Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fetrastobart vedotin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Fetrastobart vedotin (also known as Fetra-V, PF-08046054, or SGN-PDL1V) is an investigational antibody-drug conjugate (ADC) targeting programmed death-ligand 1 (PD-L1). Originally developed by Seagen and subsequently advanced by Pfizer following its acquisition of Seagen, the drug consists of a humanized anti-PD-L1 monoclonal antibody (fetrastobart) conjugated to the microtubule-disrupting cytotoxic payload monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl-valine-citrulline (mc-vc) linker. Fetrastobart vedotin is designed to selectively bind to PD-L1-expressing cancer cells, internalize, and release MMAE to induce direct tumor cell death, bystander killing, and immunogenic cell death. It is primarily being evaluated in Phase 3 clinical trials for the treatment of previously treated PD-L1-positive non-small cell lung cancer (NSCLC) and is also under investigation for other advanced solid tumors.
- Other names
- Fetra-VPDL1VPDL-1VPDL 1V
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on fetrastobart vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fetrastobart vedotin.